# US 2019/0376145 A1 · Prediction of poor response to neoadjuvant chemoradiation in rectal cancer patients using a dna repair score

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376145 A1
- Document ID: US20190376145A1
- Status: Published application
- Kind: A1
- Application number: 16/439,027
- Filed: 2019-06-12
- Published: 2019-12-12
- Earliest claimed: 2018-06-12
- Assignees: The Cleveland Clinic Foundation
- Applicants: The Cleveland Clinic Foundation
- Inventors: Matthew Kalady; Anamaria Aranha Camargo; Rodrigo Oliva Perez
- Web page: https://patentgrep.com/patent/US20190376145A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 25/10: Gene or protein expression profiling; Expression-ratio estimation or normalisation
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

One aspect of the present disclosure relates to a method for predicting the response of a patient having rectal cancer to neoadjuvant chemoradiation therapy. The method can include determining a DNA repair score. The DNA repair score can be based on DNA repair genes whose expression levels are associated with a response to neoadjuvant chemoradiation. A low DNA repair score as compared to a predetermined threshold value is indicative of a poor response to the neoadjuvant chemoradiation therapy.

## Claims

### Claim 1

A method for predicting the response of a patient having rectal cancer to neoadjuvant chemoradiation therapy (nCRT) comprising determining a DNA repair score, where a low DNA repair score as compared to a predetermined threshold value is indicative of a poor response to the nCRT.

### Claim 2 (depends on 1)

The method of claim 1, wherein the DNA repair score is determined by a method comprising:
(a) obtaining a tumor biopsy sample from the patient;
(b) assaying the biopsied tumor sample to determine expression values of DNA repair genes associated with a good response to nCRT and a poor response to nCRT; and
(b) calculating the DNA repair score based on the expression values of the DNA repair genes associated with a good response to nCRT and a poor response to nCRT.

### Claim 3 (depends on 2)

The method of claim 2, wherein step (b) further comprises:
(a) multiplying the expression values of the DNA repair genes associated with a good response to nCRT by +1 to obtain a good response to nCRT weighted gene expression values;
(b) multiplying the expression values of the DNA repair genes associated with a poor response to nCRT by −1 to obtain a poor response to nCRT weighted gene expression values; and
(c) determining the DNA repair score by calculating the sum of the weighted gene expression values obtained in (a) and (b).

### Claim 4 (depends on 3)

The method of claim 3, wherein the expressed DNA repair genes associated with a good response to nCRT are selected from the group consisting of XPA, XRCC3, UBE2A, APEX2, ATRIP and NEIL2.

### Claim 5 (depends on 3)

The method of claim 3, wherein the expressed DNA repair genes associated with a poor response to nCRT are XRCC4 and/or HTLF.

### Claim 6 (depends on 5)

The method of claim 5, wherein the expressed DNA repair gene associated with a poor response to nCRT is XRCC4.

### Claim 7 (depends on 4)

The method of claim 4, wherein the expressed DNA repair genes associated with a good response to nCRT are XPA, XRCC3, UBE2A, APEX2, and NEIL2.

### Claim 8 (depends on 2)

The method of claim 2, wherein expression values for the DNA repair genes are determined using qRT-PCR, RNA-Seq, microarrays, or a combination thereof.

### Claim 9

A method for treating a patient having rectal cancer, the method comprising:
determining a DNA repair score of the patient; and
administering a rectal cancer treatment, other than neoadjuvant chemoradiation therapy (nCRT), if the patient's DNA repair score is low as compared to a predetermined threshold value indicative of a poor response to nCRT.

### Claim 10 (depends on 9)

The method of claim 9, wherein the DNA repair score is determined by a method comprising:
(a) obtaining a tumor biopsy sample from the patient;
(b) assaying the biopsied tumor sample to determine expression values of DNA repair genes associated with a good response to nCRT and a poor response to nCRT; and
(b) calculating the DNA repair score based on the expression values of the DNA repair genes associated with a good response to nCRT and a poor response to nCRT.

### Claim 11 (depends on 10)

The method of claim 10, wherein step (b) further comprises:
(a) multiplying the expression values of the DNA repair genes associated with a good response to nCRT by +1 to obtain good response to nCRT weighted gene expression values;
(b) multiplying the expression values of the DNA repair genes associated with a poor response to nCRT by −1 to obtain poor response to nCRT weighted gene expression values; and
(c) determining the DNA repair score by calculating the sum of the weighted expression values obtained in steps (a) and (b).

### Claim 12 (depends on 11)

The method of claim 11, wherein the expressed DNA repair genes associated with a good response to nCRT are selected from the group consisting of XPA, XRCC3, UBE2A, APEX2, ATRIP and NEIL2.

### Claim 13 (depends on 11)

The method of claim 11, wherein the expressed DNA repair genes associated with a poor response to nCRT are XRCC4 and/or HTLF.

### Claim 14 (depends on 13)

The method of claim 13, wherein the expressed DNA repair gene associated with a poor response to nCRT is XRCC4.

### Claim 15 (depends on 11)

The method of claim 11, wherein the expressed DNA repair genes associated with a good response to nCRT are XPA, XRCC3, UBE2A, APEX2, and NEIL2.

### Claim 16 (depends on 10)

The method of claim 10, wherein expression values for the DNA repair genes are determined using qRT-PCR, RNA-Seq, microarrays, or a combination thereof.
